Evolving trends in the initial locoregional management of male breast cancer

Breast

Volumn 21, Issue 3, 2012, Pages 296-302

  Bratman, Scott V ^a   Kapp, Daniel S ^a   Horst, Kathleen C ^a  

^a STANFORD CANCER INSTITUTE   (United States)

Author keywords

Locoregional therapy; Male breast cancer; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; HUMAN; MALE; MALE BREAST; MASTECTOMY; PARTIAL MASTECTOMY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURGICAL TECHNIQUE; TREATMENT FAILURE; TREND STUDY; UNITED STATES;

EID: 84862519426     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2012.01.008     Document Type: Article

References (61)

1. Speirs V., Shaaban A.M. The rising incidence of male breast cancer. Breast Cancer Res Treat 2009, 115:429-430.
2. Anderson W.F., Jatoi I., Tse J., Rosenberg P.S. Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol 2010, 28:232-239.
3. Alali L., Honarpisheh H., Shaaban A., Speirs V. Conditions of the male breast: gynaecomastia and male breast cancer (Review). Mol Med Rep 2010, 3:21-26.
4. Fentiman I.S., Fourquet A., Hortobagyi G.N. Male breast cancer. Lancet 2006, 367:595-604.
5. Johansen Taber K.A., Morisy L.R., Osbahr A.J., Dickinson B.D. Male breast cancer: risk factors, diagnosis, and management (Review). Oncol Rep 2010, 24:1115-1120.
6. Lee S.C., Ellis R.J. Male breast cancer during finasteride therapy. J Natl Cancer Inst 2004, 96:338-339.
7. Shenoy N.K., Prabhakar Finasteride S.M., Breast Male Cancer: does the MHRA report show a link?. J Cutan Aesthet Surg 2010, 3:102-105.
8. Miao H., Verkooijen H.M., Chia K.S., Bouchardy C., Pukkala E., Laronningen S., et al. Incidence and outcome of male breast cancer: an international population-based study. J Clin Oncol 2011, 29:4831-4836.
9. Cutuli B., Lacroze M., Dilhuydy J.M., Velten M., De Lafontan B., Marchal C., et al. Male breast cancer: results of the treatments and prognostic factors in 397 cases. Eur J Cancer 1995, 31A:1960-1964.
10. Agrawal A., Ayantunde A.A., Rampaul R., Robertson J.F. Male breast cancer: a review of clinical management. Breast Cancer Res Treat 2007, 103:11-21.
11. Yu E., Suzuki H., Younus J., Elfiki T., Stitt L., Yau G., et al. The impact of post-mastectomy radiation therapy on male breast cancer patients - a case series. Int J Radiat Oncol Biol Phys 2012, 82:696-700.
12. Zhou F.F., Xia L.P., Guo G.F., Wang X., Yuan Z.Y., Zhang B., et al. Changes in therapeutic strategies in Chinese male patients with breast cancer: 40 years of experience in a single institute. Breast 2010, 19:450-455.
13. Gnerlich J.L., Deshpande A.D., Jeffe D.B., Seelam S., Kimbuende E., Margenthaler J.A. Poorer survival outcomes for male breast cancer compared with female breast cancer may be attributable to in-stage migration. Ann Surg Oncol 2010, [Epub ahead of print].
14. Buchholz T.A. Radiation therapy for early-stage breast cancer after breast-conserving surgery. N Engl J Med 2009, 360:63-70.
15. Smith B.D., Arthur D.W., Buchholz T.A., Haffty B.G., Hahn C.A., Hardenbergh P.H., et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys 2009, 74:987-1001.
16. Edge S.B. American Joint Committee on cancer: AJCC cancer staging manual 2009, Springer, New York. 7th ed.
17. Carlson R.W., Allred D.C., Anderson B.O., Burstein H.J., Carter W.B., Edge S.B., et al. Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2009, 7:122-192.
18. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
19. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966, 50:163-170.
20. Cox D. Regression models and life tables. J Roy Stat Soc Ser B-Stat Methodol 1972, 34:187.
21. Giuliano A.E., Hunt K.K., Ballman K.V., Beitsch P.D., Whitworth P.W., Blumencranz P.W., et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011, 305:569-575.
22. Fisher B., Jeong J.H., Anderson S., Bryant J., Fisher E.R., Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002, 347:567-575.
23. Golshan M., Rusby J., Dominguez F., Smith B.L. Breast conservation for male breast carcinoma. Breast 2007, 16:653-656.
24. Lanitis S., Filippakis G., Al Mufti R., Hadjiminas D.J. Breast conserving surgery with preservation of the nipple-areola complex as a feasible and safe approach in male breast cancer: a case report. J Med Case Rep 2008, 2:126.
25. Stranzl H., Mayer R., Quehenberger F., Prettenhofer U., Willfurth P., Stoger H., et al. Adjuvant radiotherapy in male breast cancer. Radiother Oncol 1999, 53:29-35.
26. Aberizk W.J., Silver B., Henderson I.C., Cady B., Harris J.R. The use of radiotherapy for treatment of isolated locoregional recurrence of breast carcinoma after mastectomy. Cancer 1986, 58:1214-1218.
27. Darby S., McGale P., Correa C., Taylor C., Arriagada R., Clarke M., et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011, 378:1707-1716.
28. Jagsi R., Raad R.A., Goldberg S., Sullivan T., Michaelson J., Powell S.N., et al. Locoregional recurrence rates and prognostic factors for failure in node-negative patients treated with mastectomy: implications for postmastectomy radiation. Int J Radiat Oncol Biol Phys 2005, 62:1035-1039.
29. Krag D.N., Anderson S.J., Julian T.B., Brown A.M., Harlow S.P., Costantino J.P., et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 2010, 11:927-933.
30. Veronesi U., Paganelli G., Viale G., Luini A., Zurrida S., Galimberti V., et al. Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol 2006, 7:983-990.
31. Bartelink H., Horiot J.C., Poortmans P., Struikmans H., Van den Bogaert W., Barillot I., et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 2001, 345:1378-1387.
32. Bartelink H., Horiot J.C., Poortmans P.M., Struikmans H., Van den Bogaert W., Fourquet A., et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol 2007, 25:3259-3265.
33. Romestaing P., Lehingue Y., Carrie C., Coquard R., Montbarbon X., Ardiet J.M., et al. Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. J Clin Oncol 1997, 15:963-968.
34. Bentzen S.M., Agrawal R.K., Aird E.G., Barrett J.M., Barrett-Lee P.J., Bliss J.M., et al. The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 2008, 9:331-341.
35. Bentzen S.M., Agrawal R.K., Aird E.G., Barrett J.M., Barrett-Lee P.J., Bliss J.M., et al. The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 2008, 371:1098-1107.
36. Whelan T.J., Pignol J.P., Levine M.N., Julian J.A., MacKenzie R., Parpia S., et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010, 362:513-520.
37. Vaidya J.S., Joseph D.J., Tobias J.S., Bulsara M., Wenz F., Saunders C., et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet 2010, 376:91-102.
38. Polgar C., Fodor J., Major T., Nemeth G., Lovey K., Orosz Z., et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast carcinoma-5-year results of a randomized trial. Int J Radiat Oncol Biol Phys 2007, 69:694-702.
39. Mannino M., Yarnold J. Accelerated partial breast irradiation trials: diversity in rationale and design. Radiother Oncol 2009, 91:16-22.
40. Pinkhasov R.M., Shteynshlyuger A., Hakimian P., Lindsay G.K., Samadi D.B., Shabsigh R. Are men shortchanged on health? Perspective on life expectancy, morbidity, and mortality in men and women in the United States. Int J Clin Pract 2010, 64:465-474.
41. Reinders J.G., Heijmen B.J., Olofsen-van Acht M.J., van Putten W.L., Levendag P.C. Ischemic heart disease after mantlefield irradiation for Hodgkin's disease in long-term follow-up. Radiother Oncol 1999, 51:35-42.
42. King V., Constine L.S., Clark D., Schwartz R.G., Muhs A.G., Henzler M., et al. Symptomatic coronary artery disease after mantle irradiation for Hodgkin's disease. Int J Radiat Oncol Biol Phys 1996, 36:881-889.
43. Giordano S.H., Kuo Y.F., Freeman J.L., Buchholz T.A., Hortobagyi G.N., Goodwin J.S. Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst 2005, 97:419-424.
44. Kachnic L.A., Powell S.N. IMRT for breast cancer-balancing outcomes, patient selection, and resource utilization. J Natl Cancer Inst 2011, 103:777-779.
45. Dogan N., Cuttino L., Lloyd R., Bump E.A., Arthur D.W. Optimized dose coverage of regional lymph nodes in breast cancer: the role of intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2007, 68:1238-1250.
46. Whelan T., Olivotto I., Ackerman I., Chapman J., Chua B., Nabid A., et al. NCIC-CTG MA.20: an intergroup trial of regional nodal irradiation in early breast cancer. J Clin Oncol 2011, 29. (Suppl; abstr LBA1003).
47. Matzinger O., Heimsoth I., Poortmans P., Collette L., Struikmans H., Van Den Bogaert W., et al. Toxicity at three years with and without irradiation of the internal mammary and medial supraclavicular lymph node chain in stage I to III breast cancer (EORTC trial 22922/10925). Acta Oncol 2010, 49:24-34.
48. Chen R.C., Lin N.U., Golshan M., Harris J.R., Bellon J.R. Internal mammary nodes in breast cancer: diagnosis and implications for patient management - a systematic review. J Clin Oncol 2008, 26:4981-4989.
49. Ribeiro G. Male breast carcinoma-a review of 301 cases from the Christie Hospital & Holt Radium Institute, Manchester. Br J Cancer 1985, 51:115-119.
50. Fogh S., Hirsch A.E., Langmead J.P., Goldberg S.I., Rosenberg C.L., Taghian A.G., et al. Use of tamoxifen with postsurgical irradiation may improve survival in estrogen and progesterone receptor-positive male breast cancer. Clin Breast Cancer 2011, 11:39-45.
51. Ribeiro G., Swindell R. Adjuvant tamoxifen for male breast cancer (MBC). Br J Cancer 1992, 65:252-254.
52. Liukkonen S., Saarto T., Maenpaa H., Sjostrom-Mattson J. Male breast cancer: a survey at the Helsinki University Central Hospital during 1981-2006. Acta Oncol 2010, 49:322-327.
53. Wang-Rodriguez J., Cross K., Gallagher S., Djahanban M., Armstrong J.M., Wiedner N., et al. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-neu, and p53 with treatment and survival, a study of 65 cases. Mod Pathol 2002, 15:853-861.
54. Callari M., Cappelletti V., De Cecco L., Musella V., Miodini P., Veneroni S., et al. Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer. Breast Cancer Res Treat 2010, 127:601-610.
55. Johansson I., Nilsson C., Berglund P., Strand C., Jonsson G., Staaf J., et al. High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer. Breast Cancer Res Treat 2010, 129:747-760.
56. Fong P.C., Boss D.S., Yap T.A., Tutt A., Wu P., Mergui-Roelvink M., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361:123-134.
57. Tutt A., Robson M., Garber J.E., Domchek S.M., Audeh M.W., Weitzel J.N., et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376:235-244.
58. Hasle H., Clemmensen I.H., Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 2000, 355:165-169.
59. Satge D., Sasco A.J., Pujol H., Rethore M.O. [Breast cancer in women with trisomy 21]. Bull Acad Natl Med 2001, 185:1239-1252. discussion 1252-1234.
60. Korde L.A., Zujewski J.A., Kamin L., Giordano S., Domchek S., Anderson W.F., et al. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol 2010, 28:2114-2122.
61. Speirs V., Pollock S., Shaaban A.M., Hanby A.M. Problems (and solutions) in the study of male breast cancer. Rare Tumors 2010, 2:e28.